China Antibacterial (Antibiotics) Drugs Market Analysis Report 2022 to 2030

China Antibacterial (Antibiotics) Drugs Market Analysis

$ 3999

China Antibacterial (Antibiotics) Drugs Market is at around $4.09 Bn in 2023 and is projected to reach $6.03 Bn in 2030, exhibiting a CAGR of 5.7% during the forecast period. The market is growing as a result of factors such as rising healthcare expenditures, improving healthcare infrastructure, and an increase in the incidence of infectious diseases. The market is dominated by key players like China Resources Pharmaceutical Group (CR Pharma), Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Jiangsu Hengrui, Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.

ID: IN10CNPH005 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Aneri Parekh

Buy Now

China Antibacterial (Antibiotics) Drugs Market Executive Summary

China Antibacterial (Antibiotics) Drugs Market is at around $4.09 Bn in 2023 and is projected to reach $6.03 Bn in 2030, exhibiting a CAGR of 5.7% during the forecast period.

The manufacturing activities of pharmaceutical companies, regulatory frameworks that control antibiotic use, market trends, and factors that influence demand such as healthcare infrastructure and the prevalence of infectious diseases are all components of the China antibiotics market. It is essential for stakeholders, such as healthcare professionals, politicians, and pharmaceutical companies operating within China's healthcare sector, to have a solid understanding of the dynamics of this industry.

Growing awareness of antimicrobial resistance and growing healthcare costs are expected to propel the China Antibiotics Market's substantial rise. Strong demand for antibiotics in healthcare facilities and an increasing focus on preventative healthcare practices are important causes. To deal with new bacterial strains and regulatory changes, industry players are coming up with creative solutions, which are encouraging competitiveness and technological development. Nonetheless, obstacles like counterfeit goods and legal restrictions necessitate tactical adjustment for long-term market growth.

In recent years, there has been a discernible shift in the antibiotic industry. In 2023, the market brought in $50.91 Bn in revenue, and the market is expected to rise further. The primary causes of this growth are the creation of new items and infectious diseases. These developments have been facilitated by the need for novel antimicrobial formulations, more R&D, and antibiotic prescriptions. Urbanization and the development of new antibiotics affect market expansion.

With a market share of about 5% in the whole pharmaceutical market, China Resources Pharmaceutical Group (CRPG) is ranked among the top 10 pharmaceutical businesses in China. CRPG has a market share of around 8-10% in the antibiotics market, making it a significant player. They manufacture several well-known antibiotic products, such as Cefuroxime, Levofloxacin, and Azithromycin. Additionally, the business has a strong national distribution network that reaches pharmacies, hospitals, and other healthcare facilities.

China antibacterial (antibiotics) drugs market

Market Dynamics

Market Growth Drivers:

Increasing Incidence of Infectious Diseases: The expanding prevalence of infectious diseases in China, combined with population expansion, urbanization, and international travel, promotes antibiotic demand.

Improving Healthcare Infrastructure: China is spending extensively in rural hospitals, clinics, and pharmacies. This expansion increases healthcare and antibiotic availability, driving market growth.

Rising Awareness and Healthcare Expenditure: Chinese awareness of healthcare and infectious diseases, rising disposable incomes, and government attempts to expand healthcare access increase antibiotic investment.

Market Restraints:

Regulatory Obstacles: To control antibiotic resistance, China has been proactively attempting to regulate the use of antibiotics. The market's supply, distribution, and availability of antibiotics may be impacted by strict laws and policies.

Growing Knowledge of Antibiotic Side Effects: Consumers are becoming more aware of the negative effects of antibiotics, including allergic reactions, disruption of the gut flora, and the emergence of bacteria resistant to the drugs. In certain situations, this awareness might result in a decline in the demand for antibiotics.

Competition from Traditional Chinese Medicine (TCM): In China, Western antibiotics compete with traditional Chinese medicine, which emphasizes natural remedies and holistic approaches. Antibiotic demand may be impacted by consumers who favor TCM over antibiotics.

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA) is a national drug regulatory office under the State Council of China. The State Administration for Market Regulation is in charge of it. A New Drug Application (NDA) is sent by the applicant to the NMPA. The NMPA reviews the NDA before conducting an on-site inspection of the applicant's production facilities. The applicant may be requested to provide additional clinical data or other relevant information by the NMPA. The NMPA's regulations are subject to frequent change, thus they require constant monitoring and modification.

Competitive Landscape

Key Players:

China Resources Pharmaceutical Group (CR Pharma)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Jiangsu Hengrui
Pfizer Inc.
Roche
Novartis AG
GlaxoSmithKline plc
Abbott Laboratories
Johnson & Johnson
Merck & Co., Inc.
Sanofi S.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Antibacterial (Antibiotics) Drugs Market Segmentation

By Drug Class

Cephalosporins
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
7-ACA
Others

By Type

Branded Antibiotics
Generic Antibiotics

By Action Mechanism

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

By Spectrum

Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic

By Administration

Oral
Intravenous
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.